Roivant Neurosciences Ltd. has entered into an agreement with GlaxoSmithKline to acquire SB742457, a selective 5-HT6 receptor antagonist with the potential to improve cognition and function in multiple central nervous system disorders.   GSK conducted 13 clinical studies of SB742457 in more than 1,250 healthy subjects and Alzheimer’s disease patients. The results provide evidence that SB742457 holds promise for patients with mild-to-moderate Alzheimer’s disease. Roivant will continue...